Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19251360 | 0.78 | — | — | |
| SCHEMBL19756407 | 0.76 | IDO1 (0.32) | L3MBTL1 | |
| SCHEMBL18120361 | 0.75 | ACACB (0.39) | NPC1 | |
| SCHEMBL25337982 | 0.74 | NPC1 (0.46) | KDM4ENPC1BRD4MITFL3MBTL1 | |
| SCHEMBL19756419 | 0.74 | MEN1 (0.30) | NPC1 | |
| SCHEMBL15044982 | 0.73 | NPC1 (0.32) | NPC1 | |
| SCHEMBL25368687 | 0.73 | KDM4E (0.34) | KDM4ENPC1BRD4MITFL3MBTL1 | |
| SCHEMBL19105520 | 0.70 | TYR (0.31) | — | |
| SCHEMBL16386816 | 0.69 | IDO1 (0.57) | KDM4ENPC1L3MBTL1 | |
| SCHEMBL20376503 | 0.68 | KDM4E (0.31) | HSD17B10KDM4ENPC1BRD4MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369498-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369498-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | HSD17B10 356/4885KDM4E 2371/4885NPC1 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.